| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss | |||||||||
-15,237 | -11,371 | -10,497 | -14,968 | -19,115 | -19,209 | -8,819 | -7,146 | -17,790 | -19,034 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation and amortization | |||||||||
333 | 675 | 786 | 723 | 291 | 141 | 72 | 86 | 77 | 114 |
Stock-based compensation expense | |||||||||
1,193 | 1,101 | 1,439 | 1,179 | 1,227 | 1,149 | 842 | 1,281 | 3,286 | 1,900 |
Gain on extinguishment of debt | |||||||||
- | - | - | - | 37 | 0 | - | - | - | - |
Foreign currency loss on liquidation | |||||||||
- | - | - | - | - | - | - | 153 | - | - |
Gain on sale of investments | |||||||||
- | - | - | - | - | - | - | - | - | 58 |
Change in fair value of warrants | |||||||||
- | - | - | - | - | - | - | - | 378 | -4,353 |
Common stock issued for debtor's incentive plan with related parties | |||||||||
- | - | - | - | - | - | - | - | - | 4,969 |
Non-cash license revenue | |||||||||
- | - | - | - | 316 | 454 | 454 | 454 | 454 | 867 |
Debt conversion costs | |||||||||
- | - | - | - | - | - | - | - | - | 141 |
Loss on sale and disposal of property and equipment | |||||||||
-54 | -11 | -4 | -6 | 0 | - | - | -2 | - | -56 |
Warrants issued for services | |||||||||
- | - | - | - | - | 22 | 34 | 14 | 4 | - |
Gain from sale of instrument business to Bio-Rad | |||||||||
- | - | - | - | - | - | - | 1,830 | - | - |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable | |||||||||
138 | 81 | -70 | 188 | -80 | -206 | 236 | 38 | -37 | 136 |
Prepaid expenses and other assets | |||||||||
209 | 92 | -28 | -142 | 106 | 162 | 24 | 31 | -462 | 385 |
Inventories | |||||||||
-67 | -10 | 9 | 6 | 87 | 0 | - | - | - | - |
Decrease in other assets | |||||||||
- | - | - | - | - | - | - | -2 | -10 | 12 |
Accounts payable, accrued liabilities and other liabilities | |||||||||
971 | 380 | 50 | -851 | -129 | 1,500 | 225 | -2,292 | 253 | 63 |
Net cash used in operating activities | |||||||||
-12,966 | -9,367 | -8,129 | - | - | - | - | - | -15,581 | -20,935 |
Deferred revenue | |||||||||
- | - | - | - | -173 | -1 | 136 | -61 | -497 | 595 |
Decrease in other liabilities | |||||||||
- | - | - | - | - | - | - | -52 | -207 | - |
Reorganization items | |||||||||
- | - | - | - | - | - | - | 32 | - | - |
Reorganization Items | |||||||||
- | - | - | - | - | - | - | - | -384 | -3,928 |
Net cash used in operating activities | |||||||||
- | - | - | -13,963 | -18,365 | -16,808 | -8,224 | -10,398 | - | - |
Cash flows from investing activities: | |||||||||
Purchase of property and equipment | |||||||||
133 | 113 | 60 | 1,261 | 282 | 258 | 321 | 14 | 99 | 180 |
Proceeds from the sale of instrument business to Bio-Rad | |||||||||
- | - | - | - | - | - | - | 1,830 | - | - |
Proceeds from sales of investments | |||||||||
- | - | - | - | - | - | - | - | - | -465 |
Proceeds from sale of property and equipment | |||||||||
1 | - | - | - | - | - | - | - | - | 5 |
Repurchase of common stock | |||||||||
- | - | - | - | 1,291 | 0 | - | - | - | - |
Issuance costs related to 2014 private placement | |||||||||
- | - | - | - | 122 | 0 | - | - | - | - |
Principal repayment of short-term debt | |||||||||
- | - | - | - | - | - | - | 5,894 | - | - |
Proceeds from maturity of CD pledged as collateral on letter of credit | |||||||||
- | - | - | - | - | - | - | - | - | 60 |
Net cash used in investing activities | |||||||||
-132 | -113 | -60 | - | - | - | - | - | -99 | 350 |
Construction in progress | |||||||||
- | - | - | - | 773 | 0 | - | - | - | - |
Net cash used in investing activities | |||||||||
- | - | - | -1,261 | -1,055 | -258 | - | 1,816 | - | - |
Cash flows from financing activities: | |||||||||
Proceeds from exercise of common stock warrants, net of issuance costs | |||||||||
- | - | 3,576 | - | - | - | - | - | - | - |
Proceeds from public offering of preferred stock, net of issuance costs | |||||||||
- | 4,496 | - | - | - | - | - | - | - | - |
Repayment of debtor-in-possession loan financing | |||||||||
- | - | - | - | - | - | - | - | - | -400 |
Proceeds from public offering of common stock, net of issuance costs | |||||||||
13,521 | 8,990 | - | - | - | - | - | - | 20,206 | 42,782 |
Proceeds from issuance of common stock in conjunction with the exercise of the underwriter’s option to purchase additional shares in connection with a public offering, net of issuance costs | |||||||||
2,092 | - | - | - | - | - | - | - | - | - |
Proceeds from exercise of common stock warrants, net of issuance costs | |||||||||
- | - | - | 0 | - | 10,288 | 17,647 | - | - | - |
Proceeds from issuance of DECD loan, net of issuance costs | |||||||||
- | - | - | 1,967 | - | - | - | - | - | - |
Principal repayment of DECD loan | |||||||||
189 | 185 | 183 | 118 | - | - | - | - | 5,000 | - |
Repayment of short-term debt | |||||||||
- | - | - | - | 1,069 | 0 | - | - | - | - |
Proceeds from issuance of DECD loan, net of issuance costs | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Principal repayment of DECD loan | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Repayment of capital lease obligations | |||||||||
- | 29 | 34 | 30 | 13 | 0 | - | - | - | - |
Proceeds from issuance of common stock from exercise of stock options | |||||||||
- | - | 5,127 | 0 | 17,495 | 0 | 11,751 | - | - | - |
Proceeds from issuance of common stock from exercise of stock options | |||||||||
17 | 29 | - | 5 | 97 | 239 | 644 | 6 | 34 | 42 |
Net cash provided by financing activities | |||||||||
- | - | - | 1,824 | 15,097 | 10,527 | 30,042 | -5,888 | - | - |
Costs related to issuance of common stock from warrant exercises | |||||||||
- | - | - | - | - | - | - | - | - | 133 |
Issuance costs related to conversion of convertible senior notes | |||||||||
- | - | - | - | - | - | - | - | - | 46 |
Net cash used in financing activities | |||||||||
15,441 | 13,301 | 8,486 | - | - | - | - | - | 15,240 | 40,050 |
Net decrease in cash and cash equivalents | |||||||||
2,343 | 3,821 | 297 | - | - | - | - | - | - | - |
Effect of exchange rate changes on cash and cash equivalents | |||||||||
- | - | - | - | - | - | - | - | 3 | 9 |
Net increase / (decrease) in cash and cash equivalents | |||||||||
- | - | - | -13,400 | -4,323 | -6,539 | 21,497 | -14,470 | -437 | 19,474 |
Supplemental disclosure of cash flow information: | |||||||||
Cash paid during the period for interest | |||||||||
38 | 44 | 47 | 38 | 7 | 0 | - | 227 | 462 | 1,407 |
Non-cash investing and financing activities: | |||||||||
Supplemental disclosure of noncash investing and financing activities: | |||||||||
Net increase in other assets/other liabilities for right of use assets | |||||||||
52 | - | - | - | - | - | - | - | - | - |
Deemed dividend on warrant repricing | |||||||||
- | - | 942 | 0 | - | - | - | - | - | - |
Equipment acquired through capital lease agreements | |||||||||
- | - | - | - | 107 | 0 | - | - | - | - |
Changes in other current liabilities related to equipment | |||||||||
- | - | - | - | 125 | 0 | - | - | - | - |
Income taxes | |||||||||
- | - | - | - | - | - | - | - | 0 | 0 |
Principal reduction from conversion of senior convertible notes | |||||||||
- | - | - | - | - | - | - | - | - | -170 |
Principal reduction from forgiveness of Quest secured line of credit | |||||||||
- | - | - | - | - | - | - | - | - | -3,000 |
Issuance of common stock from warrant exercise | |||||||||
- | - | - | - | - | - | - | - | - | 1,059 |
Issuance of common stock from conversion of principal and interest for senior convertible notes | |||||||||
- | - | - | - | - | - | - | - | - | 504 |